After Oppenheimer and H.C. Wainwright gave Oric Pharmaceuticals (NASDAQ: ORIC) a Buy rating last month, the company received another Buy, this time from Robert W. Baird. Analyst Colleen M. Kusy reiterated a Buy rating on Oric Pharmaceuticals yesterday and set a price target of $45.00. The company’s shares closed last Thursday at $25.98.
According to TipRanks.com, Kusy is a 1-star analyst with an average return of -1.6% and a 25.0% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Harpoon Therapeutics, and Surface Oncology.
Currently, the analyst consensus on Oric Pharmaceuticals is a Strong Buy with an average price target of $46.25, a 78.8% upside from current levels. In a report issued on March 16, Oppenheimer also maintained a Buy rating on the stock with a $52.00 price target.
See today’s analyst top recommended stocks >>
Oric Pharmaceuticals’ market cap is currently $858.5M and has a P/E ratio of -12.20. The company has a Price to Book ratio of 4.96.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.
